Skip to content
Screener

Dianthus Therapeutics DNTH Total Liabilities

Total Liabilities at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$116.09B+1.0%
Amgen logo
AmgenAMGN
$937M-15.5%
Vor Biopharma logo
Vor BiopharmaVOR
$657.17M+1,420%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$42.03M+49.1%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$6.29M-34.4%
CTO
Citius Oncology, Inc.CTOR
$65.43M+17.3%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.15B+838%
Enterprise value$5.52B+758%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemMarch 31,2026December 31,2025
Total current liabilities38,28330,732
Deferred revenue6,3225,770
Long-term operating lease liabilities9651,019
Total liabilities45,57037,521
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock; $0.001 par value per share; authorized shares – 10,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding – none at March 31, 2026 and December 31, 2025
Common stock; $0.001 par value per share; authorized shares – 150,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding shares –54,582,749 and 43,223,090 at March 31, 2026 and December 31, 2025, respectively5443

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's total liabilities?
Dianthus Therapeutics (DNTH) reported total liabilities of $45.57M in Q1 2026.
How has Dianthus Therapeutics's total liabilities changed year-over-year?
Dianthus Therapeutics's total liabilities increased by 128.1% year-over-year, from $19.97M to $45.57M.
What is the long-term trend for Dianthus Therapeutics's total liabilities?
Over 5 years (2020 to 2025), Dianthus Therapeutics's total liabilities has grown at a 16.2% compound annual growth rate (CAGR), from $17.71M to $37.52M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Dianthus Therapeutics's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude